TPI Provides Progress Updates on its GMOL Flagship Product
26 Apr, 2012, 06:04 ET
CHENGDU, China, April 26, 2012 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided updates on the sales expansion of TPI's flagship product: Gingko Mihuan Oral Liquid or GMOL (SFDA: H20013079), a prescription medicine that is used by physicians for cardiovascular conditions such as stroke, coronary heart diseases, angina, etc. (additional information: www.sfda.gov.cn, (Chinese version); or http://baike.baidu.com/view/3029034.htm). GMOL contributes approximately 50% of TPI's core product portfolio that consists of GMOL, Apu Shuangxin Granules (Apu), Azithromycin Tablets (Azi), Xuelian Chongcao (XLCC) and Qingre Jiedu Oral Liquid (QR) and approximately 30% of TPI's total revenue.
Under the ongoing healthcare reform policy that favors the sale of products that are listed in the Essential Drug List (EDL) in China, the national or provincial EDL listing could substantially support the market development of these products. GMOL has been recently selected as an EDL drug in both Henan province and Shandong province (with combined population of approximately 200 million) EDL provincial supplementary lists. The EDL status grants a full insurance coverage or 100% government reimbursement for patients.
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com, or email [email protected]
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
SOURCE Tianyin Pharmaceutical Co., Inc.
Share this article